The cyclin-dependent kinase 1 (CDK1) has been identified as a key contributor to oxaliplatin resistance in CRC, highlighting the prospect of CDK1 inhibitors for treating oxaliplatin-resistant CRC patients [109]. The gene discussed is CDK1; the disease is colorectal carcinoma.